A Case of Pulmonary Alveolar Proteinosis Improved with Inhaled Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF).
- Author:
Bo Hyoung KANG
1
;
Ho Su LEE
;
Yumi LEE
;
So Eun PARK
;
Woo Sung KIM
;
Dong Soon KIM
;
Jin Woo SONG
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Pulmonary alveolar proteinosis;
Granulocyte-macrophage colony-stimulating factor;
Administration, inhalation
- MeSH:
Administration, Inhalation;
Autoantibodies;
Biopsy;
Dyspnea;
Granulocyte-Macrophage Colony-Stimulating Factor;
Humans;
Lung;
Lung Diseases;
Male;
Middle Aged;
Pulmonary Alveolar Proteinosis;
Therapeutic Irrigation
- From:Korean Journal of Medicine
2012;82(3):357-361
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of lipoproteinaceous material within the alveoli. Several studies have recently found that autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) play a major role in the pathogenesis of idiopathic PAP. Consequently, inhaled or systemic injection of GM-CSF has been suggested as a promising treatment for PAP. A 54-year-old male visited our hospital for progressive dyspnea. Four years earlier, he was diagnosed with PAP based on a surgical lung biopsy in another institution. Whole-lung lavage was performed four times before he visited our hospital. We administered high-dose inhaled GM-CSF therapy for 12 weeks followed by 12 weeks of low-dose therapy. After the GM-CSF treatment, the patient's symptoms, lung function, and radiological findings were improved significantly.
